Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of ...

SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional

Related Keywords

China ,Illinois ,United States ,Canada ,University Of Illinois ,America ,Rick Rodgers ,Paul Hoelscher ,Dave Happel ,Maria Yonkoski ,Jinzi Wu ,Asia Pacific ,George Kemble ,Tim Walbert ,Sagimet Biosciences ,Mirum Pharmaceuticals ,Amgen ,Raptor Pharmaceutical Corp ,Nasdaq ,Merck Co ,Mallinckrodt Pharmaceuticals ,Reneo Pharmaceuticals Inc ,Neopharm Inc ,Gd Searle Company ,University Of Illinois At Urbana Champaign ,Pharma Inc ,Exchange Commission ,Aurinia Pharmaceuticals ,Takeda America Holdings Inc ,Sucampo Pharmaceuticals Inc ,Leukemia Lymphoma Society ,Sagimet Biosciences Inc ,Horizon Therapeutics ,Takeda America Holdings ,Latin America ,Century Therapeutics ,Reneo Pharmaceuticals ,Illinois Region ,Lymphoma Society ,Greater China ,Private Securities Litigation Reform Act ,Region ,